Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 5 institutions in 3 countries.
Salum J LidengeDepartment of Clinical Research, Training, and Consultancy, Ocean Road Cancer Institute, Dar es Salaam P.O. Box 3592, Tanzania.ORCID 0000-0002-0574-6595
Dicle YalcinDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0001-5616-6059
Sydney J BennettDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0002-4181-8461
Owen NgalamikaDermatology and Venereology Division, University Teaching Hospital, University of Zambia School of Medicine, Lusaka P.O. Box 50001, Zambia.ORCID 0000-0002-0648-4128
Brenda B KweyambaDepartment of Clinical Research, Training, and Consultancy, Ocean Road Cancer Institute, Dar es Salaam P.O. Box 3592, Tanzania.
Chacha J MwitaDepartment of Clinical Research, Training, and Consultancy, Ocean Road Cancer Institute, Dar es Salaam P.O. Box 3592, Tanzania.
For Yue TsoDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Julius MwaiselageDepartment of Clinical Research, Training, and Consultancy, Ocean Road Cancer Institute, Dar es Salaam P.O. Box 3592, Tanzania.
John T WestDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Charles WoodDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0002-4256-1530
Louisiana State University Health Sciences Center New Orleans · USMuhimbili University of Health and Allied Sciences · TZOcean Road Cancer Institute · TZUniversity of Nebraska–Lincoln · USUniversity Teaching Hospital · ZM
Funding
Supplement: Fogarty Training in HIV- and AIDS Associated Diseases/MalignanciesD43TW001429 · FIC · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2000 to 2015
$7.2M
Project 3U54CA277846 · NCI · LSU HEALTH SCIENCES CENTER · PI Charles Wood · 2023 to 2026
$4.7M
Seroprevalence of COVID-19 of cancer patients in TanzaniaU54CA190155 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI SOLIMAN, AMR, WOOD, CHARLES · 2014 to 2022
$4.5M
Zambia AIDS Malignancies Diagnosis and Pathogenesis Program SupplementU54CA221204 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2017 to 2022
$3.8M
KSHV,HIV and the Kaposi's Sarcoma Tumor NicheR01CA228178 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WEST, JOHN T., WOOD, CHARLES · 2018 to 2024
$2.9M
AIDS Malignancies Training and Research International Program (AMTRIP)D43TW010354 · FIC · UNIVERSITY OF NEBRASKA LINCOLN · PI Chipepo Kankasa, Charles Wood · 2016 to 2026
$2.8M
Tanzania AIDS Malignancies Training and Research Program (TAMTRP)D43TW012277 · FIC · LSU HEALTH SCIENCES CENTER · PI WOOD, CHARLES · 2022 to 2025
$1.4M
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"K43TW011418 · FIC · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI LIDENGE, SALUM JUMA · 2019 to 2023
$741k
Biomarkers of Kaposi sarcoma recrudescence in ZambiaK43TW011095 · FIC · UNIVERSITY OF ZAMBIA · PI NGALAMIKA, OWEN · 2018 to 2023
Seasonal coronaviruses (HCoVs) are known to contribute to cross-reactive antibody (Ab) responses against SARS-CoV-2. While these responses are predictable due to the high homology between SARS-CoV-2 and other CoVs, the impact of these responses on susceptibility to SARS-CoV-2 infection in cancer patients is unclear. To investigate the influence of prior HCoV infection on anti-SARS-CoV-2 Ab responses among COVID-19 asymptomatic individuals with cancer and controls without cancers, we utilized the VirScan technology in which phage immunoprecipitation and sequencing (PhIP-seq) of longitudinal plasma samples was performed to investigate high-resolution (i.e., epitope level) humoral CoV responses. Despite testing positive for anti-SARS-CoV-2 Ab in the plasma, a majority of the participants were asymptomatic for COVID-19 with no prior history of COVID-19 diagnosis. Although the magnitudes of the anti-SARS-CoV-2 Ab responses were lower in individuals with Kaposi sarcoma (KS) compared to non-KS cancer individuals and those without cancer, the HCoV Ab repertoire was similar between individuals with and without cancer independent of age, sex, HIV status, and chemotherapy. The magnitudes of the anti-spike HCoV responses showed a strong positive association with those of the anti-SARS-CoV-2 spike in cancer patients, and only a weak association in non-cancer patients, suggesting that prior infection with HCoVs might play a role in limiting SARS-CoV-2 infection and COVID-19 disease severity.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients. · full record | OpenQuestion